Dr Reddy's Laboratories announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz (Neostigmine Methylsulfate) Injection approved by the U. S. Food and Drug Administration (USFDA).
The Bloxiverz brand and generic had U.
S. sales of approximately $111 million MAT for the most recent twelve months ending in July 2018 according to IMS Health.
Dr. Reddy's Neostigmine Methylsulfate Injection, USP is available in 5 mg/10 ml and 10 mg/10 ml multi-dose vials
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)